The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
May 2nd 2024
A recent meta-analysis that assessed prescribed exercise in managing multiple sclerosis (MS) detailed the benefits of resistance training for improving muscle weakness in this patient population.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Researchers Identify New Subtype of Multiple Sclerosis
September 5th 2018New study findings have identified a subtype of multiple sclerosis—myelocortical multiple sclerosis—that has neuronal loss but no demyelination of the brain’s white matter, indicating that demyelination and neuronal degeneration occur independently.
Read More
Human–Machine Hybrid Predictions Led to Better Prognoses of MS, Study Finds
August 31st 2018Researchers evaluating the different methods used to predict the progression of multiple sclerosis (MS) found that human–machine hybrid predictions led to better prognoses than did machine learning algorithms or groups of humans alone.
Read More
Mapping the Nervous System May Shed Light on the Origin of Different Neurological Diseases
August 24th 2018Researchers recently developed a systematic map of the cell types that make up the mouse nervous system which has the ability to reveal new information about the origin of neurological diseases, and may lead to a detailed map of the human brain.
Read More
Vitamin D3 Status and MS Susceptibility is Genotype Dependent, Study Finds
August 17th 2018A recent study found that the association between vitamin D (Vit D) status and multiple sclerosis (MS) susceptibility is genotype dependent and suggested that the outcome of Vit D status in MS is determined by gene-by-sex interactions.
Read More
MRI Can Predict Progression to MS in Patients With Clinically Isolated Syndrome
August 15th 2018A study recently published in Brain and Behavior has shown that certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis (MS) within the first year following diagnosis of clinically isolated syndrome (CIS).
Read More
A recent study aimed to evaluate the burden of age of onset of cardiovascular conditions in a US population with multiple sclerosis, neuromyelitis optica spectrum disorder, or transverse myelitis and found that cardiovascular conditions are as common in those with demyelinating diseases compared with unaffected individuals.
Read More
Early-Phase Results Promising for BTK Inhibitor in Multiple Sclerosis Therapy
August 10th 2018A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.
Read More
Study Identifies IVM as Potential Candidate to Promote Remyelination for MS
August 3rd 2018A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation, finding that P2X4 receptors modulate microglia/macrophage inflammatory responses and identify allosteric modulator ivermectin (IVM) as a potential candidate to promote the repair of myelin damage.
Read More
Study Investigates Protein Receptor Subtype for Promoting Remyelination in MS
July 27th 2018Multiple sclerosis (MS) involves the progressive loss of the protective layer of nerve fibers, myelin, and its loss, called demyelination, results in symptoms of MS. Blocking the protein receptor, muscarinic type 3 (M3R), may be effective in promoting remyelination in patients with MS, based on the results of a study published by the Journal of Neuroscience.
Read More
Quantitative Susceptibility Mapping More Effective Than Brain Atrophy Imaging in Monitoring MS
July 26th 2018A study published in the journal Radiology has found that lower susceptibility in the thalamic and higher susceptibility in the basal ganglia, measured using quantitative susceptibility mapping, was associated with patients with MS and MS disease progression.
Read More
Brain Iron Levels Associated With Disability, Disease Progression in MS
July 20th 2018A recent study published in Radiology found that evaluating the differences in iron accumulation in the deep gray matter of the brain using a magnetic resonance imaging (MRI) technique may help to identify patients with multiple sclerosis (MS) that are at greater risk for disease progression and disability.
Read More
Patients With Multiple Sclerosis Need Better Dietary Education From Providers
July 19th 2018A recent study published in the European Journal of Clinical Nutrition found that healthcare professionals are downplaying the importance of patients with multiple sclerosis (MS) following national dietary guidelines.
Read More
Mindfulness-Based Interventions Are Feasible and Effective for Patients With MS
July 13th 2018Psychological stress and emotional well-being are important targets for multiple sclerosis (MS) research and clinical care. Mood disorders can adversely impact functioning, quality of life, and treatment adherence, and increase the risk of suicide.
Read More
Recent Studies Use Annualized Relapse Rate to Assess Treatments for MS
July 6th 2018A recent study evaluated the annualized relapse rate of patients with relapsing multiple sclerosis (MS) who were treated with ozanimod—an oral once-daily immunomodulator that selectively targets sphingosine 1-phosphate receptors 1 and 5—in the RADIANCE Part B study.
Read More
Epigenetic Regulation of HLA Region Increases Risk of Multiple Sclerosis
June 29th 2018A new study conducted at the Karolinska Institutet in Sweden has discovered an epigenetic regulatory mechanism of the human leukocyte antigen (HLA) region of the DNA, which can lead to an increased risk of multiple sclerosis.
Read More
Neurofilament Light Prevalence Predicts Disease Progression in RRMS
June 22nd 2018In a recent study presented at the European Academy of Neurology Annual Meeting held in Lisbon, Portugal, from June 16 to 19, researchers found that the levels of neurofilament light chain (NfL) can be a reliable predictor of disease worsening in relapsing-remitting multiple sclerosis (RRMS) patients.
Read More
Rituximab Shows Clinical Benefit in Treating Both Progressive and Relapsing-Remitting MS
June 15th 2018Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) in a single tertiary care center in Switzerland.
Read More
Updated Clinical Trial Results and Approval Progress for MS Ocrelizumab Treatment
June 8th 2018Ocrelizumab (Ocrevus) has been FDA approved for the treatment of primary progressive multiple sclerosis, and recent clinical trials with the anti-CD20 monoclonal antibody have revealed significant decreases in disease activity and disability progression in relapsing multiple sclerosis.
Read More
MS Drug Could Reduce Adverse Events Associated With Cancer Treatment
June 4th 2018In a recent study published in the Journal of Experimental Medicine, researchers found that fingolimod (sold as Gilenya), an FDA-approved orally administered drug to treat multiple sclerosis, could reduce painful side effects of multiple myeloma treatments.
Read More
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27th 2018There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
Watch